デフォルト表紙
市場調査レポート
商品コード
1466567

月経困難症治療薬市場:タイプ、治療法、流通チャネル、エンドユーザー別 - 2024年~2030年の世界予測

Dysmenorrhea Treatment Market by Type (Primary Dysmenorrhea, Secondary Dysmenorrhea), Treatment (Medication, Surgery, Therapeutics), Distribution Channel, End-Users - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 189 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
月経困難症治療薬市場:タイプ、治療法、流通チャネル、エンドユーザー別 - 2024年~2030年の世界予測
出版日: 2024年04月17日
発行: 360iResearch
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

月経困難症治療薬市場規模は2023年に71億6,000万米ドルと推計され、2024年には78億米ドルに達し、CAGR 8.98%で2030年には130億9,000万米ドルに達すると予測されます。

月経困難症治療薬は、月経困難症や月経痛に伴う疼痛や不快感を管理・緩和するための治療アプローチを指します。月経困難症は、月経期間中または月経前に発生する痛みを伴う腹部けいれんを特徴とし、月経中の個人のかなりの割合に影響を及ぼす一般的な疾患です。月経困難症の治療法は、痛みを軽減し、生活の質を向上させ、日常生活への支障を最小限に抑えることを目的としています。一方、女性のリプロダクティブ・ヘルスに対する意識の高まりや、女性のためのヘルスケア施設を支援する政府の取り組みやプログラムは、月経困難症関連治療の拡大に大きく貢献しています。臨床試験の増加やヘルスケア事業体による莫大な投資も、大規模な月経困難症治療薬と診断に寄与しています。しかし、月経痛治療薬に関連する償還政策の欠如と厳しい規制は、月経困難症治療薬プロバイダーにとって大きな課題です。企業は、この進化する市場情勢の中で競争力を維持するために、治療費の削減や新薬の研究活動への投資を継続的に行っています。さらに、月経困難症の治療における最近の進歩や、デジタルヘルスサービスとともにウェアラブル技術の採用が増加していることも、月経困難症治療薬の今後の拡大に頻繁に寄与しています。さらに、人工知能や機械学習を用いたデータ主導型の洞察力を活用することで、パーソナライズされた治療計画の策定や、月経困難症治療薬における新たな治療介入につながるパターンの特定にも役立ちます。

主な市場の統計
基準年[2023] 71億6,000万米ドル
予測年[2024] 78億米ドル
予測年 [2030] 130億9,000万米ドル
CAGR(%) 8.98%

タイプ原発性月経困難症の幅広い発生と疼痛緩和管理の広範なニーズ

原発性月経困難症は、月経中の子宮収縮とプロスタグランジンの放出によって引き起こされ、最大90%の女性が経験しています。主な月経困難症治療薬は疼痛緩和と管理です。その他の治療法としては、ホルモンレベルの調整に役立つ経口避妊薬、筋肉の緊張を和らげる温熱療法、運動やストレス軽減などの生活習慣の改善が挙げられます。二次性月経困難症は、子宮内膜症、骨盤内炎症性疾患、子宮筋腫などの基礎疾患が原因で起こる月経痛です。二次性の月経困難症治療薬の必要性は、症状の緩和と同時に、痛みの根本原因に対処することに重点を置いています。続発性月経困難症の治療法は、特定の疾患によって異なります。子宮内膜症の治療には、ホルモン療法、腹腔鏡手術などの外科的介入、抗炎症薬などがあります。骨盤内炎症性疾患が続発性月経困難症の根本的な原因である場合は、感染症を治療するために抗生物質が処方されることが多いです。

治療月経困難症からの永続的な解放のための子宮摘出治療の採用

薬物療法は、月経困難症の治療の第一選択となることが多いです。イブプロフェンやナプロキセンなどの非ステロイド性抗炎症薬(NSAIDs)は、月経痛に伴う痛みや炎症を効果的に抑えます。これらの薬は市販されているか、ヘルスケア専門家によって処方されます。外科的介入による治療は、子宮内膜症や子宮筋腫などの基礎疾患が原因で月経困難症が重症化している患者さんに限られます。腹腔鏡手術は低侵襲で、痛みの原因となっている癒着や筋腫を効果的に取り除くことができます。極端な場合には、子宮を摘出する子宮摘出術を行うことで、月経困難症から永久的に解放されることがあります。さらに、心理的介入は、月経困難症に関連した精神的苦痛に対処し、全体的な対処能力を高めるのに有益です。最も用いられる心理療法には、認知行動療法(CBT)、リラクゼーション法(深呼吸、漸進的筋弛緩法)、バイオフィードバック(心拍変動、筋緊張、皮膚温などの生理的プロセスのモニタリング)などがあります。さらに、さまざまな非薬理学的アプローチが、重大な副作用を引き起こすことなく月経困難症の症状を管理する潜在的な利点のために人気を集めています。鍼治療、経皮的電気神経刺激(TENS)、アロマセラピー、ヨガ、栄養補助食品などの代替療法はほとんどなく、月経困難症の症状を管理する非薬理学的方法を求める人々にさまざまな選択肢を提供し、月経痛を経験する患者に包括的なケアの選択肢を提供しています。

流通チャネル:利便性、慎重さ、薬や鎮痛パッチの競合価格設定により、オンライン薬局への嗜好が高まっています。

月経困難症の治療において、病院薬局は患者に即座に適切な薬を提供する上で極めて重要です。病院薬局には、非ステロイド性抗炎症薬(NSAIDs)、鎮痛薬、鎮痙薬、経口避妊薬を含むホルモン治療薬など、さまざまなタイプの月経困難症を治療するための市販薬(OTC)や処方薬が幅広く揃っていることが多いです。オンライン薬局は、その利便性、慎重さ、競争力のある価格設定により、月経困難症治療薬を購入する上でますます人気が高まっています。オンライン・プラットフォームでは、従来のOTC医薬品や、ハーブサプリメントやヒートパッチなどの代替療法など、さまざまな製品を提供しています。オンライン薬局は、プライバシーを重視する人々や、実店舗へのアクセスが限られた遠隔地に住む人々の間で選好度が高いです。小売薬局は、ヘルスケア専門家への事前のアポイントメントを必要とせず、簡単に薬にアクセスできるため、月経困難症治療薬にとって不可欠な流通チャネルであり続けています。これらの薬局では、イブプロフェン、ナプロキセン、アスピリンなど、様々なOTC薬を在庫しています。小売薬局は、個別的なアドバイスや推奨のために薬剤師と対面することを好む消費者に対応しています。

エンドユーザー:ホームケア分野での月経困難症治療薬の採用増加:アクセスが容易で費用対効果も高いため

ホームケア分野では、エンドユーザーは月経困難症の症状を管理するために、簡単にアクセスでき、費用対効果の高い治療オプションを好みます。これには、非ステロイド性抗炎症薬(NSAIDs)、イブプロフェン、ナプロキセンなどの市販薬(OTC)、温熱療法やハーブサプリメントなどの自然療法が含まれます。ホームケアでは、ヨガ、鍼治療、マッサージなどの代替療法も行われるが、これらは月経痛の緩和に有望な結果を示しています。重症の月経困難症の治療には、より集中的なケアや高度な介入を必要とするため、エンドユーザーは病院を好みます。また、重度の月経困難症の症状を引き起こしている婦人科的基礎疾患がある患者には、外科的治療が勧められることもあります。子宮内膜症に関連した月経痛は、病院の専門の婦人科外科医による腹腔鏡手術で治療することができます。専門クリニックは、婦人科医、生殖内分泌専門医、骨盤痛専門医など、女性の健康問題に精通した医療専門家による専門的な治療を求めるエンドユーザーに対応しています。これらのクリニックは、処方薬、ホルモン療法、理学療法、心理カウンセリングなど、個人に合わせた治療計画を提供しています。

地域的洞察

米国やカナダを含むアメリカ諸国では、女性人口の大部分が月経困難症を含む月経痛を経験しています。これらの国々では、女性の健康問題に対する意識が高まるにつれて、この症状に対する効果的な治療法を研究開発する様々な取り組みが見られます。欧州連合(EU)諸国は、女性の健康を優先する先進的なヘルスケアシステムを有しており、月経困難症治療薬の選択肢に関する調査に多額の資金を提供しています。例えば、欧州医薬品庁(EMA)は、欧州各国で月経痛緩和をターゲットとした様々な医薬品を承認しています。さらに、中国、日本、インドは、月経痛を経験する女性の人口が多いことから、アジア太平洋地域の月経困難症治療薬の主要市場となっています。これらの国々では、月経困難症への対処において伝統医療が重要な役割を果たしています。さらにこの地域では、月経困難症の治療における鍼や灸などの代替療法の有効性を探る調査も行われています。日本では、女性の健康問題に対処するために伝統医療と現代医療の混合アプローチが採用されており、月経痛緩和のためにロキソプロフェンなどの特許薬が処方されています。インドでは、女性の健康問題に対する意識の高まりとともに、月経衛生管理への投資が増加し、安価な医療へのアクセスも増えています。世界における効果的な月経困難症治療薬の必要性は、文化的要因、ヘルスケアインフラ、女性の健康問題に対する意識に基づいて、地域によって異なります。研究開発の革新は、月経困難症治療薬の選択肢を前進させる有望な機会を提供します。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは月経困難症治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、月経困難症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1.月経困難症治療薬市場の市場規模および予測は?

2.月経困難症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3.月経困難症治療薬市場の技術動向と規制枠組みは?

4.月経困難症治療薬市場における主要ベンダーの市場シェアは?

5.月経困難症治療薬市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 月経困難症の有病率と効果的な治療法の必要性
      • 女性の生殖に関する健康に関する意識の高まりと、女性向けヘルスケアの拡大に向けた政府の取り組み
    • 抑制要因
      • 月経困難症治療薬および医療機器の製品リコールに関連する問題
    • 機会
      • 月経困難症治療の進歩と新薬の登場
      • ウェアラブル技術の導入とデジタルヘルスの普及
    • 課題
      • 月経困難症の管理に関する社会的障壁と偏見
  • 市場セグメンテーション分析
    • タイプ:原発性月経困難症が広く発生し、痛みの緩和管理が広範囲に必要となる
    • 治療:月経困難症を永久的に緩和するために子宮摘出治療を採用する
    • 流通チャネル:利便性、機密性、医薬品や鎮痛パッチの競争力のある価格設定により、オンライン薬局が好まれる傾向が高まっています。
    • エンドユーザー:アクセスが容易でコスト効率が高いため、ホームケア分野での月経困難症治療薬の採用が増加しています。
  • 市場動向分析
    • 南北アメリカでは、先進的な医薬品オプションとスタートアップによるイノベーションの成長が特徴で、パーソナライズされたデジタルかつ患者中心のソリューションを提供することを目指しています。
    • 女性の健康意識の高まりにより、アジア太平洋地域全体での大規模な臨床試験と月経困難症治療薬商品化が必要
    • 規制遵守では、EMEA地域における月経困難症治療薬の資金調達、研究開発、臨床試験、承認を重視します。
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制枠組みの分析

第6章 月経困難症治療薬市場:タイプ別

  • 原発性月経困難症
  • 二次性月経困難症

第7章 月経困難症治療薬市場:治療法別

  • 手術
  • 治療薬

第8章 月経困難症治療薬市場:流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 月経困難症治療薬市場:エンドユーザー別

  • ホームケア
  • 病院
  • 専門クリニック

第10章 南北アメリカの月経困難症治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋の月経困難症治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの月経困難症治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析、2023年
  • FPNVポジショニングマトリックス、2023年
  • 競合シナリオ分析
    • ミスラ、月経困難症治療薬として日本で販売承認申請
    • チャイム・バイオロジクスとホープ・メディシンが製造契約を締結、子宮内膜症と男性型脱毛症を標的とした初の抗体医薬品HMI-115の発売を加速
    • ミスラ、日本での月経困難症治療薬に富士製薬から250万ユーロを受領
    • 住友製薬とファイザー、カナダでMYFEMBREEのカナダ保健省承認を取得
    • ゲデオン・リヒターと住友製薬、子宮内膜症治療薬RYEQOについてCHMPの肯定的見解を取得
    • モントリオール発の新技術が生理痛対策に役立つ可能性
    • 中外製薬とバイオフォーミス、子宮内膜症に伴う疼痛に対するデータ駆動型バーチャルケアに重点を置いた新たな提携を締結
    • デア・バイオサイエンス、原発性月経困難症治療の第1相試験を開始
    • ヘルステックのスタートアップ企業Oviraは、薬を使わない生理痛緩和という重要な問題に取り組む女性たちを支援しています。
    • コーラは、美しさにインスパイアされた新しいデザインとウェルネスポートフォリオの拡大により、生理ケアを再考し、誰もが快適に過ごせるようにします。

第14章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. DYSMENORRHEA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DYSMENORRHEA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DYSMENORRHEA TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. DYSMENORRHEA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. DYSMENORRHEA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DYSMENORRHEA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRIMARY DYSMENORRHEA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SECONDARY DYSMENORRHEA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE PILLS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE PILLS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY COX-2 INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY OVER-THE-COUNTER MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TRANSDERMAL GLYCERYL TRINITRATE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY TRANSDERMAL GLYCERYL TRINITRATE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HYSTERECTOMY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY INTRAUTERINE DEVICE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPIC UTEROSACRAL NERVE ABLATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LAPAROSCOPIC UTEROSACRAL NERVE ABLATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LEVONORGESTREL INTRAUTERINE SYSTEM (LN-IUS), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY LEVONORGESTREL INTRAUTERINE SYSTEM (LN-IUS), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESACRAL NEURECTOMY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PRESACRAL NEURECTOMY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ALTERNATIVE THERAPIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PSYCHOLOGICAL THERAPIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY PSYCHOLOGICAL THERAPIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL DYSMENORRHEA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 90. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 97. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 100. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 101. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 104. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 105. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 106. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 107. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 111. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 118. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 119. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 120. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 121. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 124. CANADA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 125. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 128. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 129. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 132. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 133. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 134. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 135. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 136. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 137. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 138. MEXICO DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 139. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 142. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 143. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 146. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 147. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 148. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 149. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 152. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 153. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 154. UNITED STATES DYSMENORRHEA TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC DYSMENORRHEA TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 171. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 174. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 178. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 180. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 184. AUSTRALIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 185. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 188. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 189. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 190. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 191. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 192. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 193. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 194. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 195. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 196. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 197. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 198. CHINA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 199. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 206. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 207. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 208. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 209. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 210. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 211. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 212. INDIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 213. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 216. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 217. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 218. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 219. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 220. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 221. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 222. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 223. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 226. INDONESIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 227. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 230. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 231. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 232. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 233. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 234. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 235. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 236. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 237. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 240. JAPAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 241. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 248. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 249. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 250. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 251. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 254. MALAYSIA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 255. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 258. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 259. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 260. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 261. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 262. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 263. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 264. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 265. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 266. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 267. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 268. PHILIPPINES DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 269. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 270. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 271. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 272. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 273. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 276. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 277. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 278. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 279. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 282. SINGAPORE DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 283. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 286. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 287. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 288. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 289. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 290. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 291. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 292. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 293. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 294. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 295. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 296. SOUTH KOREA DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 297. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 300. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 301. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 302. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 303. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 304. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 305. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 306. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 307. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 308. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 309. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 310. TAIWAN DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 311. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 314. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 315. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 316. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 317. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 318. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 319. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 320. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 321. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 322. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 323. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 324. THAILAND DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 325. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 328. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 329. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2018-2023 (USD MILLION)
  • TABLE 330. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY MEDICATION, 2024-2030 (USD MILLION)
  • TABLE 331. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2018-2023 (USD MILLION)
  • TABLE 332. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY SURGERY, 2024-2030 (USD MILLION)
  • TABLE 333. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 334. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 335. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 336. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 337. VIETNAM DYSMENORRHEA TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 338. VIETNAM DYSMENORRHEA TREATMENT MARK
目次
Product Code: MRR-742BD517DA92

[189 Pages Report] The Dysmenorrhea Treatment Market size was estimated at USD 7.16 billion in 2023 and expected to reach USD 7.80 billion in 2024, at a CAGR 8.98% to reach USD 13.09 billion by 2030.

Dysmenorrhea treatment refers to the therapeutic approaches for managing and alleviating the pain and discomfort associated with dysmenorrhea or menstrual cramps. Dysmenorrhea is a prevalent condition affecting a significant proportion of menstruating individuals, characterized by painful abdominal cramping that occurs during or before their menstrual periods. The treatments for treating dysmenorrhea aim to reduce the pain, improve quality of life, and minimize disruption to daily activities. Meanwhile, the rising awareness about women's reproductive health and government initiatives & programs supporting healthcare facilities for women contribute significantly to the expansion of dysmenorrhea-related treatments. The increasing number of clinical trials and huge investments by healthcare entities have also contributed to the large-scale dysmenorrhea treatments & diagnosis. However, the lack of reimbursement policies and strict regulations associated with the drugs for menstrual pains is a significant challenge for dysmenorrhea treatment providers. Companies are continuously working toward cutting treatment costs and investing in research activities for novel medications to remain competitive in this evolving market landscape. Moreover, the recent advancements in the therapy of dysmenorrhea and increasing adoption of wearable technology along with digital health services are frequently contributing to the future expansion of dysmenorrhea treatment. Additionally, harnessing data-driven insights using artificial intelligence and machine learning can also aid in developing personalized treatment plans and identifying patterns leading to new therapeutic interventions in dysmenorrhea treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 7.16 billion
Estimated Year [2024] USD 7.80 billion
Forecast Year [2030] USD 13.09 billion
CAGR (%) 8.98%

Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management

Primary dysmenorrhea is experienced by up to 90% of women which is caused by uterine contractions and prostaglandin release during menstruation. The need for primary dysmenorrhea treatment mainly revolves around pain relief and management. Additional treatments include oral contraceptives that help regulate hormone levels, heat application to ease muscle tension, and lifestyle modifications such as exercise and stress reduction. Secondary dysmenorrhea is menstrual pain caused by an underlying medical condition, including endometriosis, pelvic inflammatory disease, or uterine fibroids. The need for secondary dysmenorrhea treatment focuses on addressing the root cause of the pain while also providing symptom relief. The treatment options for secondary dysmenorrhea vary depending on the specific medical condition. Endometriosis treatments may include hormonal therapy, surgical interventions such as laparoscopic surgery, and anti-inflammatory medications. The cases having pelvic inflammatory disease is the underlying cause of secondary dysmenorrhea, antibiotics are often prescribed to treat the infection.

Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea

Medications are often the first line of treatment for dysmenorrhea. Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and naproxen, effectively reduce pain and inflammation associated with menstrual cramps. These medications are purchased over the counter or prescribed by a healthcare professional. Surgical intervention treatment is reserved for patients with severe dysmenorrhea caused by underlying conditions such as endometriosis or uterine fibroids. Laparoscopic surgery is minimally invasive and can effectively remove adhesions or fibroids causing the pain. In extreme cases, a hysterectomy, which is the removal of the uterus, may be performed to provide permanent relief from dysmenorrhea. Moreover, psychological interventions can be beneficial in addressing the emotional distress linked to dysmenorrhea and enhancing overall coping abilities. Most used psychological therapies include cognitive behavioral therapy (CBT), relaxation techniques (deep breathing, progressive muscle relaxation), and biofeedback (monitoring physiological processes such as heart rate variability, muscle tension, or skin temperature). Furthermore, various non-pharmacological approaches have gained popularity due to their potential benefits in managing dysmenorrhea symptoms without causing significant side effects. Few alternative treatments, including acupuncture, transcutaneous electrical nerve stimulation (TENS), aromatherapy, yoga, and dietary supplements, offer a variety of options for individuals seeking non-pharmacological methods to manage dysmenorrhea symptoms and provide comprehensive care options for patients experiencing menstrual pain.

Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches

In treating dysmenorrhea, hospital pharmacies are crucial in providing patients with immediate and appropriate medication. Hospital pharmacies often have a wide range of over-the-counter (OTC) and prescription medications to treat various types of dysmenorrhea, including nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, antispasmodics, and hormonal treatments, including oral contraceptives. Online pharmacies are increasingly popular for purchasing dysmenorrhea treatments due to their convenience, discreteness, and competitive pricing. Online platforms offer a variety of products, including traditional OTC medications and alternative remedies such as herbal supplements and heat patches. The preference for online pharmacies is higher among those seeking privacy or living in remote areas with limited access to physical retail outlets. Retail pharmacies remain an essential distribution channel for dysmenorrhea treatments as they offer easy access to medication without needing a prior appointment with a healthcare professional. These pharmacies stock various OTC medications, including ibuprofen, naproxen, and aspirin. Retail pharmacies cater to consumers preferring face-to-face interaction with pharmacists for personalized advice and recommendations.

End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective

In the homecare sector, end-users prefer easily accessible and cost-effective treatment options to manage dysmenorrhea symptoms. These include over-the-counter (OTC) medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, and naproxen, and natural remedies, including heat therapy and herbal supplements. Homecare also involves alternative therapies such as yoga, acupuncture, and massage that have shown promising results in alleviating menstrual pain. End-users prefer hospitals in need of more intensive care or advanced interventions for treating severe cases of dysmenorrhea. Surgical treatments may also be recommended in patients with underlying gynecological conditions contributing to severe dysmenorrhea symptoms. Endometriosis-related menstrual pain can be treated in laparoscopic surgery by specialized gynecological surgeons in hospitals. Specialty clinics cater to end-users seeking specialized care from healthcare professionals with expertise in women's health issues, such as gynecologists, reproductive endocrinologists, and pelvic pain specialists. These clinics offer personalized treatment plans, including prescription medications, hormonal therapy, physical therapy, or psychological counseling.

Regional Insights

In American countries, including the United States and Canada, a large percentage of the female population experiences menstrual cramps, including dysmenorrhea. These countries witness various efforts to research and develop effective treatments for this condition with greater awareness of women's health issues. European Union countries have advanced healthcare systems that prioritize women's health, leading to significant funding for research on dysmenorrhea treatment options. For instance, the European Medicines Agency (EMA) has approved various medications targeting menstrual pain relief across European countries. Furthermore, China, Japan, and India are key markets within the Asia-Pacific region for dysmenorrhea treatment due to their large populations of women experiencing menstrual pain. Traditional medicine plays a crucial role in addressing dysmenorrhea in these countries. Moreover, research initiatives in this region explore the efficacy of alternative therapies, such as acupuncture and moxibustion, in treating dysmenorrhea. In Japan, a mix of traditional and modern medical approaches is adopted to address women's health issues, with patented medications such as Loxoprofen being prescribed for menstrual pain relief. India has observed an increase in investment in menstrual hygiene management and access to affordable healthcare with its growing awareness about women's health issues. The need for effective dysmenorrhea treatments worldwide varies across regions based on cultural factors, healthcare infrastructure, and awareness about women's health issues. Innovations in research and development provide promising opportunities for advancements in dysmenorrhea treatment options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dysmenorrhea Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dysmenorrhea Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dysmenorrhea Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Abbott Laboratories, AbbVie Inc., Alfa Pharma GmbH, Alvogen, Inc., ASKA Pharmaceutical Co., Ltd., Bayer AG, Comforte Cream by PMS4PMS, LLC, Cora Life by LYV Life, Inc., Cumberland Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Endo Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Ferring B.V., Gedeon Richter Plc., GlaxoSmithKline PLC, Haleon PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., LGM Pharma, Livia by iPulse Medical Ltd., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Micro Labs Limited, Myoovi, Myovant Sciences by Sumitovant Biopharma, Inc., Novartis AG, Ovira, Perrigo Company PLC, Pfizer Inc., Rael, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dysmenorrhea Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Primary Dysmenorrhea
    • Secondary Dysmenorrhea
  • Treatment
    • Medication
      • Combined Oral Contraceptive Pills
      • Cox-2 Inhibitors
      • Non-Steroidal Anti-Inflammatory Drugs
      • Over-The-Counter Medications
      • Transdermal Glyceryl Trinitrate
    • Surgery
      • Hysterectomy
      • Intrauterine Device
      • Laparoscopic Uterosacral Nerve Ablation
      • Levonorgestrel Intrauterine System (LN-IUS)
      • Presacral Neurectomy
    • Therapeutics
      • Alternative Therapies
      • Psychological Therapies
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End-Users
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dysmenorrhea Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dysmenorrhea Treatment Market?

3. What are the technology trends and regulatory frameworks in the Dysmenorrhea Treatment Market?

4. What is the market share of the leading vendors in the Dysmenorrhea Treatment Market?

5. Which modes and strategic moves are suitable for entering the Dysmenorrhea Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of dysmenorrhea and the need for effective treatment options
      • 5.1.1.2. Growing awareness about women's reproductive health and government initiatives to expand healthcare for women
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls for dysmenorrhea drugs and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapy for dysmenorrhea and the emergence of novel drugs
      • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
    • 5.1.4. Challenges
      • 5.1.4.1. Societal barriers and stigmatization regarding dysmenorrhea management
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management
    • 5.2.2. Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea
    • 5.2.3. Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches
    • 5.2.4. End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective
  • 5.3. Market Trend Analysis
    • 5.3.1. Strong dysmenorrhea treatment landscape in the Americas characterized by advanced pharmaceutical options and growing innovation by startups, aiming to provide personalized, digital and patient-centered solutions
    • 5.3.2. Rising women's health awareness necessitates extensive clinical trials and dysmenorrhea treatment commercialization across APAC
    • 5.3.3. Regulatory compliance emphasizes the funding, R&D, clinical trials, and approvals for dysmenorrhea treatment in the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Dysmenorrhea Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Primary Dysmenorrhea
  • 6.3. Secondary Dysmenorrhea

7. Dysmenorrhea Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Medication
  • 7.3. Surgery
  • 7.4. Therapeutics

8. Dysmenorrhea Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Dysmenorrhea Treatment Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Dysmenorrhea Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dysmenorrhea Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dysmenorrhea Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Mithra Submits Marketing Approval Application in Japan to Combat Dysmenorrhea
    • 13.3.2. Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
    • 13.3.3. Mithra to Receive EUR 2.5 Million from Fuji Pharma for Dysmenorrhea Treatment in Japan
    • 13.3.4. Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE
    • 13.3.5. Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO for Treatment of Endometriosis
    • 13.3.6. How New Tech from Montreal Could Help the Fight Against Period Cramps
    • 13.3.7. Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
    • 13.3.8. Dare Bioscience Begins Phase I Trial of Primary Dysmenorrhea Therapy
    • 13.3.9. Healthtech Startup Ovira is Helping Women Tackle a Key Problem - Drug-Free Period Pain Relief
    • 13.3.10. Cora Reimagines Period Care with a New Beauty-Inspired Look and Expanded Wellness Portfolio to Make Comfort Accessible for Everyone

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio